Ciclosporin use in dry eye disease patients

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 3121-3128

  Ridder III, William H ^a  

^a SOUTHERN CALIFORNIA COLLEGE OF OPTOMETRY   (United States)

Author keywords

Ciclosporin; Dry eye disease; Immunomodulator; Restasis

Indexed keywords

CYCLOSPORIN A;

APOPTOSIS; APPLICATION SITE BURNING; APPLICATION SITE REACTION; APPLICATION SITE STINGING; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; GINGIVITIS; GOBLET CELL; HUMAN; HYPEROSMOLARITY; HYPERTENSION; IMMUNOMODULATION; LACRIMATION; MALAISE; NAUSEA; NEPHROTOXICITY; NERVE BLOCK; NONHUMAN; REVIEW; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; CYCLOSPORINE; DRUG TOLERANCE; DRY EYE SYNDROMES; HUMANS;

EID: 57549117962     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802500613     Document Type: Review

References (66)

1. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723-8
2. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999;159:1359-63
3. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105:1114-9
4. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol 2000;118:819-25
5. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-8
6. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26
7. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2003;31:229-32
8. Lee AJ, Lee J, Saw SM, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol 2002;86:1347-51
9. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 2003;110:1096-101
10. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop 2007. Ocul Surf 2007;5:75-92
11. Schaumberg DA. Progress on the epidemiology of dry eye syndrome. Ocul Surf 2005;3:S111
12. Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao J 1995;21:221-32
13. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61
14. Rolando M, Barabino S, Mingari C, et al. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes. Cornea 2005;24:951-4
15. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-9
16. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;45:4293-301
17. Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005;31:186-93
18. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjogren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol 2006;176:3950-7
19. Borel JF. Cyclosporin-A - present experimental status. Transplant Proc 1981;13:344-8
20. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 2006;46:105-22
21. US Food & Drug Administration, Centre for Drug Evaluation & Research. Priority NDA Approvals for Calendar Year 2002; Restasis N021023. Available from: www.fda.gov/cder/rdmt/NDAPriority02.htm [Last accessed October 1 2008]
22. Acheampong AA, Shackleton M, Tang-Liu DD, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999;18:91-103
23. Anglade E, Yatscoff R, Foster R, et al. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opin Investig Drugs 2007;16:1525-40
24. Vickers AE, Fischer V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1992;20:802-9
25. Wiederholt M, Kossendrup D, Schulz W, et al. Pharmacokinetic of topical cyclosporin A in the rabbit eye. Invest Ophthalmol Vis Sci 1986;27:519-24
26. Acheampong A, Shackleton M, Lam S, et al. Cyclosporine distribution into the conjunctiva, cornea, lacrimal gland, and systemic blood following topical dosing of cyclosporine to rabbit, dog, and human eyes. Adv Exp Med Biol 1998;438:1001-4
27. Angelov O, Wiese A, Yuan Y, et al. Preclinical safety studies of cyclosporine ophthalmic emulsion. Adv Exp Med Biol 1998;438:991-5
28. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. Clao J 1998;24:159-65
29. Kashani S, Mearza AA. Uses and safety profile of ciclosporin in ophthalmology. Expert Opin Drug Saf 2008;7:79-89
30. DeBakey ME. Cyclosporin a: a new era in organ transplantation. Compr Ther 1984;10:7-15
31. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol 1989;107:1210-6
32. BenEzra D, Matamoros N, Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 1988;20:644-9
33. Kiang E, Tesavibul N, Yee R, et al. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant 1998;22:147-51
34. Diaz-Valle D, Benitez del Castillo JM, Castillo A, et al. Immunologic and clinical evaluation of postsurgical necrotizing sclerocorneal ulceration. Cornea 1998;17:371-5
35. Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 1997;29:405-8
36. Oh C, Apel AJ, Saville BA, et al. Local efficacy of cyclosporine in corneal transplant therapy. Curr Eye Res 1994;13:337-43
37. Lelli GJ Jr, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006;25:635-8
38. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh) 1994;72:438-42
39. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993;12:315-23
40. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-74
41. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9
42. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96
43. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr Eye Res 1999;19:201-11
44. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
45. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001;42:90-5
46. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002;120:330-7
47. Pflugfelder SC, De Paiva CS, Villarreal AL, et al. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 2008;27:64-9
48. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000;19:492-6
49. Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology 1991;98:1190-6
50. Nelson JD. Impression cytology. Cornea 1988;7:71-81
51. Singh G, Lindstrom RL, Doughman DJ. Cyclosporin A on human corneal endothelium. Cornea 1984;3:272-7
52. BenEzra D. Differential effect of cyclosporin A on lymphocyte and keratocyte proliferation. Invest Ophthalmol Vis Sci 1987;(Suppl);28:42
53. Salisbury MA, Kaswan RL, Brown J. Effect of topical cyclosporine on the recovery of micro-organisms from dogs with KCS. Invest Ophthalmol Vis Sci 1994(Suppl);35:1693
54. Ryffel B. The carcinogenicity of ciclosporin. Toxicology 1992;73:1-22
55. Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet 2005;44:247-61
56. de Smet MD, Nussenblatt RB. Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin 1993;33:31-45
57. Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Ann Transplant 2001;6:25-30
58. Feutren G. The optimal use of cyclosporin A in autoimmune diseases. J Autoimmun 1992;5(Suppl A):183-95
59. Kassianides C, Nussenblatt R, Palestine AG, et al. Liver injury from cyclosporine A. Dig Dis Sci 1990;35:693-7
60. Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 2005;8:225-32
61. Aoki S, Mizote H, Minamoto A, et al. Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. Br J Ophthalmol 2005;89:243-4
62. Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 2001;20:430-4
63. Cordero-Coma M, Anzaar F, Sobrin L, et al. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm 2007;15:99-104
64. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-23
65. Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003;11:131-9
66. Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89:666-9